Resultats globals: 3 registres trobats en 0.02 segons.
Articles, 2 registres trobats
Documents de recerca, 1 registres trobats
Articles 2 registres trobats  
1.
8 p, 1.1 MB Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial / Wysham, Carol (Rockwood Clinic, Spokane, Washington) ; Bonadonna, Riccardo C. (, Department of Clinical and Experimental Medicine, University of Parma) ; Aroda, Vanita R. (Medstar Health Research Institute, Hyattsville, Maryland) ; Puig Domingo, Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Kapitza,Christoph (Profil Institute, Neuss, Germany) ; Stager, William (Sanofi, Bridgewater, New Jersey) ; Yu, Christine (Sanofi, Bridgewater, New Jersey) ; Niemoeller, Elisabeth (Sanofi, Frankfurt, Germany) ; Souhami, Elisabeth (Sanofi, Paris, France) ; Bergenstal,Richard M. (International Diabetes Center, Park Nicollet Health Services, Minneapolis, Minnesota) ; Universitat Autònoma de Barcelona
Aims: To assess the impact of baseline characteristics on clinical outcomes in the LixiLan-L trial, a randomized open-label trial designed to evaluate the efficacy and safety of iGlarLixi, a novel fixed-ratio combination of insulin glargine 100 U (iGlar) plus lixisenatide, in comparison with iGlar over 30 weeks in a population of patients with type 2 diabetes mellitus (T2DM) inadequately controlled on a previous regimen of basal insulin alone or in combination with 1 or 2 oral glucose-lowering drugs. [...]
2017 - 10.1111/dom.12961
Diabetes, Obesity and Metabolism, Vol. 19 (2017) , p. 1408-1415  
2.
9 p, 847.0 KB Is there a justification for classifying GLP-1 receptor agonists as basal and prandial? / Miñambres, Inka (Institut d'Investigació Biomèdica Sant Pau) ; Pérez Pérez, Antonio (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
Several GLP-1 receptor agonists are currently available for treatment of type 2 diabetic patients. Based on their pharmacokinetic/pharmacodynamic profile, these drugs are classified as short-acting GLP-1 receptor agonists (exenatide and lixisenatide) or long-acting GLP-1 receptor agonists (exenatide-LAR, liraglutide, albiglutide, and dulaglutide). [...]
2017 - 10.1186/s13098-017-0204-6
Diabetology & Metabolic Syndrome, Vol. 9 (january 2017)  

Documents de recerca 1 registres trobats  
1.
22 p, 1.2 MB Introducción del GLP en el mercado español de combustibles : un análisis a nivel local / Marín Sánchez, Cynthia Paola ; Perdiguero, Jordi, dir. (Universitat Autònoma de Barcelona. Departament d'Economia Aplicada) ; Universitat Autònoma de Barcelona. Facultat d'Economia i Empresa
El uso de combustibles ecológicos es un elemento fundamental para la reducción de la contaminación ambiental debido a la importante contribución que tiene el transporte terrestre en este problema. [...]
2015
Grau en Economia [952]
2 documents

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.